CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac223 · Cited by 606
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 503
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Self-citationTherapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
CAR T therapy beyond cancer: the evolution of a living drug
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A., & June, C. H. (2023) · Nature · doi:10.1038/s41586-023-06243-w · Cited by 504
Self-citationFrom bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 466
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
In vivo CAR T cell generation to treat cancer and autoimmune disease
Hunter, T. L., Bao, Y., Zhang, Y., Matsuda, D., Riener, R., Wang, A., Li, J. J., Soldevila, F., Chu, D. S. H., Nguyen, D. P., et al. (2025) · Science · doi:10.1126/science.ads8473 · Cited by 330
Self-citationIn vivo hematopoietic stem cell modification by mRNA delivery
Breda, L., Papp, T. E., Triebwasser, M. P., Yadegari, A., Fedorky, M. T., Tanaka, N., Abdulmalik, O., Pavani, G., Wang, Y., Grupp, S. A., et al. (2023) · Science · doi:10.1126/science.ade6967 · Cited by 335
Self-citationTargeting immune–fibroblast cell communication in heart failure
Amrute, J. M., Luo, X., Penna, V., Yang, S., Yamawaki, T., Hayat, S., Bredemeyer, A., Jung, I.-H., Kadyrov, F. F., Heo, G. S., et al. (2024) · Nature · doi:10.1038/s41586-024-08008-5 · Cited by 339
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 303
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina-Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 279
Self-citationBillingsley, M. M., Gong, N., Mukalel, A. J., Thatte, A. S., El‐Mayta, R., Patel, S. K., Metzloff, A. E., Swingle, K. L., Han, X., Xue, L., et al. (2024) · Small · doi:10.1002/smll.202304378 · Cited by 268
Self-citationReformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
Su, K., Shi, L., Sheng, T., Yan, X., Lin, L., Meng, C., Wu, S., Chen, Y., Zhang, Y., Wang, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50093-7 · Cited by 264
Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.019 · Cited by 254
In vivo human T cell engineering with enveloped delivery vehicles
Hamilton, J. R., Chen, E., Perez, B. S., Sandoval Espinoza, C. R., Kang, M. H., Trinidad, M., Ngo, W., & Doudna, J. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02085-z · Cited by 256
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Self-citationAbedini, A., Levinsohn, J., Klötzer, K. A., Dumoulin, B., Ma, Z., Frederick, J., Dhillon, P., Balzer, M. S., Shrestha, R., Liu, H., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01802-x · Cited by 200
Cheng, M. H. Y., Leung, J., Zhang, Y., Strong, C., Basha, G., Momeni, A., Chen, Y., Jan, E., Abdolahzadeh, A., Wang, X., et al. (2023) · Advanced Materials · doi:10.1002/adma.202303370 · Cited by 228
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wang, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 206
Melamed, J. R., Yerneni, S. S., Arral, M. L., LoPresti, S. T., Chaudhary, N., Sehrawat, A., Muramatsu, H., Alameh, M.-G., Pardi, N., Weissman, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1444 · Cited by 210
Self-citationThe future of engineered immune cell therapies
Irvine, D. J., Maus, M. V., Mooney, D. J., & Wong, W. W. (2022) · Science · doi:10.1126/science.abq6990 · Cited by 209
From concept to cure: The evolution of CAR-T cell therapy
Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N., & June, C. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.005 · Cited by 180
Self-citationHilgendorf, I., Frantz, S., & Frangogiannis, N. G. (2024) · Circulation Research · doi:10.1161/circresaha.124.323658 · Cited by 180
Lickefett, B., Chu, L., Ortiz-Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D., Hudecek, M., Kremer, A., Markman, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 178
Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications
Xie, S., Xu, S.-C., Deng, W., & Tang, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01378-8 · Cited by 177
Wang, Y.-S., Kumari, M., Chen, G.-H., Hong, M.-H., Yuan, J. P.-Y., Tsai, J.-L., & Wu, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 173
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 173
In vivo editing of lung stem cells for durable gene correction in mice
Sun, Y., Chatterjee, S., Lian, X., Traylor, Z., Sattiraju, S. R., Xiao, Y., Dilliard, S. A., Sung, Y.-C., Kim, M., Lee, S. M., et al. (2024) · Science · doi:10.1126/science.adk9428 · Cited by 183
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Bui, T. A., Mei, H., Sang, R., Ortega, D. G., & Deng, W. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105266 · Cited by 173
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Hamieh, M., Mansilla-Soto, J., Rivière, I., & Sadelain, M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0101 · Cited by 163
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
Wang, Q., Xiao, Z. X., Zheng, X., Wang, G., Yang, L., Shi, L., Xiang, N., Wang, X., Zha, G., Schett, G. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2509522 · Cited by 177
Targeted modulation of immune cells and tissues using engineered biomaterials
Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 164
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 180
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 177
Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases
Yang, P., Luo, Q., Wang, X., Fang, Q., Fu, Z., Li, J. X., Lai, Y., Chen, X., Xu, X., Peng, X., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202110-2414oc · Cited by 163
In vivo chimeric antigen receptor (CAR)-T cell therapy
Bot, A., Scharenberg, A. M., Friedman, K. M., Guey, L. T., Hofmeister, R., Andorko, J. I., Klichinsky, M., Neumann, F., Shah, J. V., Swayer, A. J., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01291-5 · Cited by 213
Self-citationCardiac fibroblasts and mechanosensation in heart development, health and disease
Pesce, M., Duda, G. N., Forte, G., Girão, H., Raya, Á., Roca‐Cusachs, P., Sluijter, J. P. G., Tschöpe, C., & Linthout, S. V. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00799-2 · Cited by 166
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Cogliati, B., Yashaswini, C. N., Wang, S., Sia, D., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00821-z · Cited by 173
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain
Han, E. L., Tang, S., Kim, D., Murray, A. M., Swingle, K. L., Hamilton, A. G., Mrksich, K., Padilla, M. S., Palanki, R., Li, J. J., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.4c05186 · Cited by 158
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 171
Nanomedicines for cardiovascular disease
Smith, B. R., & Edelman, E. R. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00232-y · Cited by 163
Philipp, J., Dabkowska, A. P., Reiser, A., Frank, K., Krzysztoń, R., Brummer, C., Nickel, B. A., Blanchet, C. E., Sudarsan, A., Ibrahim, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310491120 · Cited by 159
Vascular remodelling in cardiovascular diseases: hypertension, oxidation, and inflammation
Totoń‐Żurańska, J., Mikolajczyk, T. P., Saju, B., & Guzik, T. J. (2024) · Clinical Science · doi:10.1042/cs20220797 · Cited by 158
In vivo CAR engineering for immunotherapy
Li, Y.-R., Zhu, Y., Halladay, T., & Yang, L. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01174-1 · Cited by 172
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
Cliff, E. R. S., Kelkar, A. H., Russler‐Germain, D. A., Tessema, F. A., Raymakers, A., Feldman, W. B., & Kesselheim, A. S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397912 · Cited by 182
Lei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 173
Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 171
Self-citationZhuang, T., Chen, M., Wu, R.-X., Wang, J., Hu, X.-D., Meng, T., Wu, A.-H., Li, Y., Yang, Y., Lei, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46357-x · Cited by 151
Álvarez‐Benedicto, E., Tian, Z., Chatterjee, S., Orlando, D., Kim, M., Guerrero, E. D., Wang, X., & Siegwart, D. J. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310395 · Cited by 139
Direct in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 152
Ravassa, S., López, B., Treibel, T. A., José, G. S., Losada-Fuentenebro, B., Tapia, L., Bayés‐Genís, A., Díez, J., & González, A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101194 · Cited by 149
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 149
Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery
Hu, M., Li, X., You, Z., Cai, R., & Chen, C. (2023) · Advanced Materials · doi:10.1002/adma.202303266 · Cited by 167
The Discovery of Extracellular Vesicles and Their Emergence as a Next-Generation Therapy
Rai, A., Claridge, B., Lozano, J., & Greening, D. W. (2024) · Circulation Research · doi:10.1161/circresaha.123.323054 · Cited by 148
Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development
Chen, Q., Yang, Z., Liu, H., Man, J., Oladejo, A. O., Ibrahim, S., Wang, S., & Hao, B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050674 · Cited by 152
A new age of precision gene therapy
Schambach, A., Buchholz, C. J., Torres-Ruiz, R., Cichutek, K., Morgan, M. A., Trapani, I., & Büning, H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01952-9 · Cited by 143
Kong, W., Wei, Y., Dong, Z., Liu, W., Zhao, J., Huang, Y., Yang, J., Wu, W., He, H., & Qi, J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02812-x · Cited by 140
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 134
CAR-based therapies: opportunities for immuno-medicine beyond cancer
Aghajanian, H. K., Rurik, J. G., & Epstein, J. A. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00537-5 · Cited by 131
Self-citationClinical delivery of circular RNA: Lessons learned from RNA drug development
Young, T. L., Wang, K. C., Varley, A., & Li, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114826 · Cited by 133
The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications
Wang, X., Chen, L., Wei, J., Zheng, H., Zhou, N., Xu, X., Deng, X., Liu, T., & Zou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02220-z · Cited by 146
RNA therapeutics: updates and future potential
Zhang, C., & Zhang, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2171-2 · Cited by 130
Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering
Kitte, R., Rabel, M., Geczy, R., Park, S., Fricke, S., Koehl, U., & Tretbar, S. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101139 · Cited by 125
Mori, Y., Novruzov, E., Schmitt, D. R., Cardinale, J., Watabe, T., Choyke, P. L., Alavi, A. A., Haberkorn, U., & Giesel, F. L. (2024) · npj Imaging · doi:10.1038/s44303-024-00053-z · Cited by 137
Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure
Ghazal, R., Wang, M., Liu, D., Tschumperlin, D. J., & Pereira, N. L. (2025) · Circulation Research · doi:10.1161/circresaha.124.325402 · Cited by 139
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 126
Haghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 130
Gao, M., Li, Y., Ho, W., Chen, C., Chen, Q., Li, F., Tang, M., Fan, Q., Wan, J., Yu, W., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c09817 · Cited by 128
Programmable eukaryotic protein synthesis with RNA sensors by harnessing ADAR
Jiang, K., Koob, J. G., Chen, X. D., Krajeski, R. N., Zhang, Y., Volf, V., Zhou, W., Sgrizzi, S. R., Villiger, L., Gootenberg, J. S., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01534-5 · Cited by 122
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 129
CAR-T Cell Therapy: From the Shop to Cancer Therapy
Uscanga‐Palomeque, A. C., Chávez-Escamilla, A. K., Alvizo-Báez, C. A., Saavedra-Alonso, S., Terrazas-Armendáriz, L. D., Támez-Guerra, R., Rodríguez-Padilla, C., & Alcocer-González, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115688 · Cited by 129
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Dai, H., Zhu, C., Huai, Q., Xu, W., Zhu, J., Zhang, X., Zhang, X., Sun, B., Xu, H., Zheng, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.034 · Cited by 114
Simonsen, J. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.022 · Cited by 116
Recent advances in nanoparticulate RNA delivery systems
Witten, J. J., Hu, Y., Langer, R., & Anderson, D. G. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307798120 · Cited by 120
Lipid nanoparticles: Composition, formulation, and application
Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 124
Smart and versatile biomaterials for cutaneous wound healing
Li, M., Xia, W., Khoong, Y., Huang, L., Huang, X., Liang, H., Zhao, Y., Mao, J., Yu, H., & Zan, T. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00426-2 · Cited by 125
Hamilton, A. G., Swingle, K. L., Joseph, R. A., Mai, D., Gong, N., Billingsley, M. M., Alameh, M., Weissman, D., Sheppard, N. C., June, C. H., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301515 · Cited by 112
Self-citationThe Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022) · Pharmaceuticals · doi:10.3390/ph15070897 · Cited by 109
Mittelheisser, V., Gensbittel, V., Bonati, L., Li, W., Tang, L., & Goetz, J. G. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01535-8 · Cited by 109
Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis
Gao, M., Tang, M., Ho, W., Teng, Y., Chen, Q., Bu, L., Xu, X., & Zhang, X. (2023) · ACS Nano · doi:10.1021/acsnano.3c00958 · Cited by 112
New diagnostic and therapeutic strategies for myocardial infarction via nanomaterials
Shi, H., Huang, Z., Xu, T., Sun, A., & Ge, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103968 · Cited by 110
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 112
Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery
Xu, X., & Xia, T. (2023) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.2c00062 · Cited by 112
Bimbo, J. F., van Diest, E., Murphy, D. E., Ashoti, A., Evers, M. J. W., Narayanavari, S. A., Vaz, D. P., Rijssemus, H., Zotou, C., Saber, N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011759 · Cited by 107
Tang, C., Jing, W., Han, K. S., Yang, Z., Zhang, S., Liu, M., Zhang, J., Zhao, X., Liu, Y., Shi, C., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c10109 · Cited by 104
Lim, W. A. (2022) · Science · doi:10.1126/science.add9665 · Cited by 101
A Combinatorial Library of Lipid Nanoparticles for Cell Type‐Specific mRNA Delivery
Naidu, G. S., Yong, S., Ramishetti, S., Rampado, R., Sharma, P., Ezra, A., Goldsmith, M., Hazan‐Halevy, I., Chatterjee, S., Aitha, A., et al. (2023) · Advanced Science · doi:10.1002/advs.202301929 · Cited by 109
Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects
Liu, Y., Huang, Y., He, G., Guo, C., Dong, J., & Wu, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810166 · Cited by 109
Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 109
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.